UTMD: financial statements from SEC — TradeAlmanac

UTMD

Utah Medical Products, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Revenue	9m	9m	10m	10m	10m	9m	10m	10m
Cost of revenue	3m	—	4m	4m	4m	—	4m	4m
Gross profit	5m	5m	6m	6m	6m	5m	6m	6m
Research and development	154,000	—	167,000	135,000	154,000	—	172,000	255,000
Selling, general and administrative	3m	—	3m	2m	2m	—	2m	3m
Operating expenses	3m	—	3m	2m	2m	—	2m	3m
Operating income	3m	—	3m	3m	3m	—	3m	3m
Pre-tax income	3m	—	3m	4m	4m	—	4m	4m
Income tax	578,000	—	678,000	788,000	817,000	—	616,000	758,000
Net income	3m	3m	3m	3m	3m	3m	4m	3m
Earnings per share	0.82	—	0.82	0.94	0.92	—	1.02	0.98
Earnings per share, diluted	0.82	0.80	0.82	0.94	0.92	0.86	1.03	0.98
Weighted average shares	3m	—	3m	3m	3m	—	3m	4m
Weighted average shares, diluted	3m	—	3m	3m	3m	—	3m	4m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	87m	86m	84m	82m	83m	83m	88m	89m
Receivables	4m	4m	4m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	3m	4m
Depreciation and amortisation	211,000	200,000
Share-based compensation	120,000	82,000
Capital expenditure	130,000	184,000
Investing cash flow	−130,000	−184,000
Dividends paid	989,000

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)